Castration-resistant prostate cancer remains an incurable disease. The unmet clinical need to optimally select individual treatment options, and thereby maximize survival benefit, can be addressed by patient-specific preclinical models. Patient-derived organoids preserve original tumor characteristics and have shown potential for high-throughput assessments and coclinical drug testing, as highlighted for several cancer types in this review. This new patient-derived 3D culture technique and its downstream applications are the subjects of intense investigation in prostate cancer. Although challenges are not trivial, we expect a major impact on prostate cancer research, with a window of opportunities for early bench-to-bedside translation of new drug discoveries and guidance of patient-tailored disease management.

Additional Metadata
Keywords Drug screens, Organoids, Personalized medicine, Prostate cancer
Persistent URL dx.doi.org/10.1016/j.coemr.2020.02.005, hdl.handle.net/1765/125481
Journal Current Opinion in Endocrine and Metabolic Research
Citation
Van Hemelryk, A. (Annelies), & van Weerden, W.M. (2020). Novel patient-derived 3D culture models to guide clinical decision-making in prostate cancer. Current Opinion in Endocrine and Metabolic Research (Vol. 10, pp. 7–15). doi:10.1016/j.coemr.2020.02.005